NutraLife BioSciences Inc. (NLBS)
| Market Cap | 16.45M |
| Revenue (ttm) | 1.20M |
| Net Income (ttm) | n/a |
| Shares Out | 163.40M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $0.1013 |
| Previous Close | $0.1151 |
| Change ($) | -0.0138 |
| Change (%) | -11.99% |
| Day's Open | 0.1001 |
| Day's Range | 0.0951 - 0.1048 |
| Day's Volume | 68,600 |
| 52-Week Range | 0.0260 - 0.1800 |
News
Coconut Creek, FL, July 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- NutraLife Biosciences, Inc. (“NutraLife” or the “Company”) (OTC: NLBS) is pleased to announce that it has obtained current, fully...
About NLBS
NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil, topical lotions and oils, massage oils, and internal pet products. The company also offers NutraHemp CBD products, including oral sprays, tinctures, pet drops, pain balms, and face creams; and nutraceutical oral spray products for sleep support and weight loss; and an appetite suppressant, as well as dietary and other... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 2010 |
| Stock Exchange OTCMKTS | Ticker Symbol NLBS |
Financial Performance
In 2019, NLBS's revenue was $2.13 million, a decrease of -42.51% compared to the previous year's $3.71 million. Losses were -$4.01 million, 93.2% more than in 2018.